Study details
Enrolling now
Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia
Vishwajit Nimgaonkar, MD PhD
NCT IDNCT03794076ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
160
Study length
about 7.3 years
Ages
18–65
Locations
1 site in PA
About this study
Researchers are testing whether cromoglicate, a treatment, can help people with schizophrenia. The trial will last 2647 days and involve approximately 160 participants. Participants will be randomly assigned to receive either cromoglicate or a placebo.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Cromoglycate
- 2.Take Placebo
PhasePhase 1/Phase 2
Primary goalImprovement in positive symptoms
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low8%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Improvement in positive symptoms
Secondary: Cognition, Negative Symptoms, Quality of Life Scale (QOL), Total Symptoms
Body systems
Psychiatry / Mental Health